



# Prior Authorization Request

VERZENIO (abemaciclib)

## Instructions

Please complete Part A and have your physician complete Part B. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. Please note that you have the right to appeal the decision made by Express Scripts Canada.

## Part A – Patient

### Patient information

First Name:		Last Name:	
Insurance Carrier Name/Number:			
Group Number:		Client ID:	
Date of Birth (YYYY/MM/DD):		Relationship: <input type="checkbox"/> Employee <input type="checkbox"/> Spouse <input type="checkbox"/> Dependent	
Language: <input type="checkbox"/> English <input type="checkbox"/> French		Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female	
Address:			
City:	Province:	Postal Code:	
Email address:			
Telephone (home):	Telephone (cell):	Telephone (work):	

### Coordination of benefits

<b>Patient Assistance Program</b>	Is the patient enrolled in any patient assistance program? <input type="checkbox"/> Yes <input type="checkbox"/> No Contact Name: _____ Fax: _____
<b>Provincial Coverage</b>	Has the patient applied for reimbursement under a provincial plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <b><i>*Attach decision letter*</i></b>
<b>Primary Coverage</b>	Has the patient applied for reimbursement under a primary plan? <input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> N/A What is the coverage decision of the drug? <input type="checkbox"/> Approved <input type="checkbox"/> Denied <b><i>*Attach decision letter*</i></b>

## Authorization

On behalf of myself and my eligible dependents, I authorize my group benefit provider, and its agents, to exchange the personal information contained on this form. I give my consent on the understanding that the information will be used solely for purposes of administration and management of my group benefit plan. This consent shall continue so long as my dependents and I are covered by, or are claiming benefits under the present group contract, or any modification, renewal, or reinstatement thereof.

\_\_\_\_\_  
Plan Member Signature

\_\_\_\_\_  
Date



# Prior Authorization Request

VERZENIO (abemaciclib)

## Part B – Prescriber

Please see instructions on page 1 and complete all sections below. Incomplete forms may result in automatic denial. Please do not provide genetic test information or results.

### SECTION 1 – DRUG REQUESTED

VERZENIO (abemaciclib)				<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request*
Dose	Administration (ex: oral, IV, etc)	Frequency	Duration		
Site of drug administration:					
<input type="checkbox"/> Home	<input type="checkbox"/> Physician's office/Infusion clinic	<input type="checkbox"/> Hospital (outpatient)	<input type="checkbox"/> Hospital (inpatient)		

\* Please submit proof of prior coverage if available

### SECTION 2 – ELIGIBILITY CRITERIA

#### 1. Please indicate if the patient satisfies the below criteria:

##### Early Breast Cancer

- For the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer in an adult, AND
- The patient is at high risk of disease recurrence based on clinicopathologic features, AND
- VERZENIO will be used in combination with endocrine therapy

##### Breast Cancer – First-Line

- For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine based therapy in an adult, AND
- The patient is a postmenopausal woman, AND
- The patient has not received prior systemic therapy in the metastatic setting, AND
- VERZENIO will be used in combination with an aromatase inhibitor

##### Breast Cancer – Second-Line

- For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in an adult, AND
- The patient is postmenopausal woman, OR
- The patient is a pre- or peri-menopausal woman and receiving treatment with a luteinizing hormone releasing hormone (LHRH) agonist (*Please list prior therapies in the chart below*), AND
- The patient's disease previously progressed on or after prior endocrine therapy (*Please list prior therapies in the chart below*), AND
- VERZENIO will be used in combination with fulvestrant



### Prior Authorization Request

VERZENIO (abemaciclib)

**Breast Cancer – Third-Line**

- For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in an adult, AND
- The patient is a woman, AND
- The patient’s disease progressed after prior endocrine therapy and at least 2 prior chemotherapy regimens (*Please list prior therapies in the chart below*), AND
- The patient received at least one chemotherapy regimen in the metastatic setting (*Please list prior therapies in the chart below*), AND
- The patient received at least one chemotherapy regimen containing a taxane (*Please list prior therapies in the chart below*), AND
- VERZENIO will be used as monotherapy

**OR**

- None of the above criteria applies.

Relevant additional information:

**2. Please list previously tried therapies**

Drug	Dosage and administration	Duration of therapy		Reason for cessation	
		From	To	Inadequate response	Allergy/ Intolerance
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>
				<input type="checkbox"/>	<input type="checkbox"/>



# Prior Authorization Request

VERZENIO (abemaciclib)

## SECTION 3 – PRESCRIBER INFORMATION

Physician's Name:	
Address:	
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

**Please fax or mail the completed form to Express Scripts Canada®**

**Fax:** Express Scripts Canada Clinical Services  
1 (855) 712-6329

**Mail:** Express Scripts Canada Clinical Services  
6985 Financial Drive, Suite 300  
Mississauga, ON, L5N 0G3